Merck to Buy Harpoon Therapeutics for $680 Million

[ad_1] Merck & Co.has struck a deal to buy clinical-stage immunotherapy company Harpoon Therapeutics for about $680 million. Merck on Monday said it will pay $23 a share in cash…

AstraZeneca to Buy Gracell Biotechnologies for $1.2 Billion

[ad_1] AstraZeneca has agreed to buy Gracell Biotechnologies for a transaction value of $1.2 billion, as part of the former’s efforts to grow its cell therapies business. The upfront cash…

Blockbuster Cancer Treatment Stymied by Supply Chain—for Now

[ad_1] A cell therapy for multiple myeloma promises to be a major blockbuster for J&J and partner Legend, if they can increase manufacturing. [ad_2] Source link

New Gene Therapy Could Face Uphill Battle Despite FDA Approval

[ad_1] The FDA approval of BioMarin’s gene therapy for hemophilia is a major win, but patient uptake could be slow. [ad_2] Source link

New Gene Therapy Could Face Uphill Battle

[ad_1] The potential FDA approval of BioMarin’s gene therapy for hemophilia A would be a major win, but patient uptake could be slow. [ad_2] Source link